Page 123 - New epidemiological and PSMA-expression based paradigms in salivary gland tumors
P. 123

PSMA PET/CT: as a tool to assess and guide salivary gland irradiation
References
[1] Pinna R, Campus G, Cumbo E, Mura I, Milia E. Xerostomia induced by radiotherapy: an overview of the physiopathology, clinical evidence, and management of the oral damage. Ther Clin Risk Manag 2015;11:171–88. doi:10.2147/TCRM.S70652.
[2] Jellema A, Slotman B, Doornaert P, Leemans C, Langendijk J. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:751–60. doi:10.1016/j.ijrobp.2007.04.021.
[3] Cheng S, Wu V, Kwong D, Ying M. Assessment of post-radiotherapy salivary glands. Br J Radiol 2011;84:393–402. doi:10.1259/bjr/66754762.
[4] Oliveira J, Gomes C, Faria D, Vieira T, Silva F, Vale J, et al. 68Ga-prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Prostate Cancer Imaging: A Narrative Literature Review. World J Nucl Med 2017;16:3–7. doi:10.4103/1450-1147.198237.
[5] Perera M, Papa N, Christidis D, Wetherell D, Hofman M, Murphy D, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926–37. doi:10.1016/j.eururo.2016.06.021.
[6] Demirci E, Sahin O, Ocak M, Akovali B, Nematyazar J, Kabasakal L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl Med Commun 2016;37:1169–79. doi:10.1097/MNM.0000000000000566.
[7] Prasad V, Steffen I, Diederichs G, Makowski M, Wust P, Brenner W. Biodistribution of [(68)Ga] PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions. Mol Imaging Biol 2016;18:428–36. doi:doi: 10.1007/s11307-016-0945-x.
[8] Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, Wetterauer U, Elsässer-Beile U. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010 Apr 1;70(5):562-9. doi: 10.1002/pros.21090.
[9] Klein Nulent TJW, Valstar MH, de Keizer B, Willems SM, Smit LA, Al-Mamgani A, et al. Physiological 7 distribution of PSMA-ligand in salivary and seromucous glands of the head and neck on PET/CT. Oral
Surg Oral Med Oral Pathol Oral Radiol 2018;125:478–86. doi:10.1016/j.oooo.2018.01.011.
[10] Backhaus P, Noto B, Avramovic N, Grubert L, Huss S, Bögemann M, et al. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur J Nucl Med Mol Imaging 2018;45:860–77. doi:10.1007/s00259-017-3922-y.
121
 




















































































   121   122   123   124   125